Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Operating Expenses (2020 - 2026)

Immuneering's Operating Expenses history spans 7 years, with the latest figure at $15.3 million for Q1 2026.

  • On a quarterly basis, Operating Expenses fell 0.97% to $15.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $59.2 million, a 7.79% decrease, with the full-year FY2025 number at $59.4 million, down 7.33% from a year prior.
  • Operating Expenses came in at $15.3 million for Q1 2026, up from $13.8 million in the prior quarter.
  • The five-year high for Operating Expenses was $18.6 million in Q4 2024, with the low at $11.7 million in Q2 2022.
  • Historically, Operating Expenses has averaged $14.7 million across 5 years, with a median of $14.8 million in 2025.
  • Biggest five-year swings in Operating Expenses: skyrocketed 98.0% in 2022 and later decreased 25.89% in 2025.
  • Year by year, Operating Expenses stood at $14.0 million in 2022, then rose by 16.56% to $16.3 million in 2023, then grew by 13.84% to $18.6 million in 2024, then fell by 25.89% to $13.8 million in 2025, then grew by 11.51% to $15.3 million in 2026.
  • Business Quant data shows Operating Expenses for IMRX at $15.3 million in Q1 2026, $13.8 million in Q4 2025, and $15.4 million in Q3 2025.